Tennis Elbow Treatment Market

Market Overview

The global tennis elbow treatment market size was valued at USD 168.8 million in 2023 and is projected to reach USD 280.4 million by 2032, registering a CAGR of 5.8% during the forecast period (2024-2032). The rising prevalence of elbow tendon swelling and increasing rates of elbow joint pain are the primary reasons driving the tennis elbow treatment market share. 

Tennis elbow treatment is multifaceted, and it relieves pain, reduces inflammation, and promotes healing in people suffering from lateral epicondylitis. This condition causes discomfort and swelling on the outside of the elbow. This comprehensive treatment regimen typically includes a combination of non-invasive therapies such as physical therapy, ultrasound therapy, and orthopedic devices such as braces, all of which aim to strengthen the affected tendons and reduce strain on the elbow joint. 

The factors driving the growth of the Tennis Elbow Treatment Market include an increase in the population aged 35 to 60, the usage of incorrect equipment by athletes, and demanding body activities. Furthermore, technological advancements contribute to the growth of the Tennis Elbow Treatment Market. The technology that involves painless treatment and allows patients to recuperate quickly is introduced. Tennis elbow is treated with the same therapy that leaves no scratches. However, the low acceptance rate of novel effective therapies will limit growth in this market during the projection period.

Highlights

• Non-surgical therapies account for the largest share of the market by treatment type.
• Elders hold the major market share through Application.

Market Dynamics

Global Tennis Elbow Treatment Market Drivers

Increasing Incidence of Tennis Elbow

As the prevalence of tennis elbow rises due to factors such as sedentary lifestyles, repetitive motions in certain occupations, and increased participation in sports, the demand for effective treatment options grows. Tennis elbow is a common musculoskeletal disorder (MSD) caused by repetitive motion. It affects 1-3% of the population yearly, or approximately 4-7 cases per 1,000 people. It is the most common cause of chronic elbow pain, accounting for roughly two-thirds of cases. Tennis elbow is estimated to affect 1 to 3 percent of the population in the United States. It typically occurs between the ages of 30 and 50.  Furthermore, a new study conducted by researchers at the University of Utah and the Rocky Mountain Center for Occupational and Environmental Health found that people with higher cardiovascular disease risk are significantly more likely to develop carpal tunnel syndrome, tennis elbow, golfer's elbow, and rotator cuff tendinitis.

Furthermore, rising participation in recreational and competitive sports, particularly those involving repetitive arm movements like tennis, golf, and weightlifting, contributes to an increase in tennis elbow among athletes of all ages. For example, data from sports medicine clinics and athletic associations show an increase in reported cases of tennis elbow among amateur and professional athletes, highlighting the need for effective treatment strategies to address the condition and reduce its impact on athletic performance and overall quality of life.

Global Tennis Elbow Treatment Market Restraints

High Cost of Advanced Treatment Modalities

While advanced treatment modalities like orthobiologics, shockwave therapy, and arthroscopic surgery have promising results, they are often prohibitively expensive. The high cost of these interventions may deter patients, particularly those without adequate insurance coverage or financial resources, from seeking the best treatment options, limiting market growth. Tennis elbow treatment, for example, can range from USD 1,000 to USD 5,000 for conservative care, which includes over-the-counter medications, massage, physical therapy, support, and cortisone injections. Surgical intervention is estimated to cost USD 16,000. Tennis elbow surgery in India can cost between INR 60,000 and INR 1,50,000 (equivalent to USD 800-USD 2,000). The same procedure can cost USD 10,000 to USD 15,000 in the United States, while prices range from 5,000 to 8,000 Pound in the United Kingdom. 

Furthermore, arthroscopic surgery for severe cases of tennis elbow can be costly, with surgeon fees, hospitalization costs, anesthesia fees, and postoperative rehabilitation expenses totaling thousands of dollars per procedure. The average price of a single platelet-rich plasma (PRP) injection ranges from USD 500 to USD 2,500, with the total cost determined by the number of sessions required and other factors. 

Similarly, shockwave therapy for tennis elbow can cost anywhere from USD 500 to USD 1,000 per session, with an average of USD 700. The cost varies depending on the clinic and your insurance coverage. Further, the high cost of advanced treatment modalities such as PRP therapy may disproportionately affect underserved populations and people with limited access to healthcare resources, exacerbating disparities in healthcare access and increasing socioeconomic barriers to receiving optimal tennis elbow treatment. 

Global Tennis Elbow Treatment Market Opportunity

Expansion of Telemedicine and Remote Rehabilitation Services

The COVID-19 pandemic has accelerated the widespread adoption of telemedicine and remote rehabilitation platforms, opening new avenues for providing accessible and convenient tennis elbow treatment solutions to patients worldwide. Telemedicine platforms enable remote consultations, diagnosis, and treatment monitoring. In contrast, virtual rehabilitation programs allow patients to receive personalized exercise regimens, ergonomic advice, and self-management strategies from the comfort of their own homes. According to a McKinsey & Company report, telehealth utilization for office visits and outpatient care increased 78 times between February 2020 and April 2020.

Furthermore, telerehabilitation services have emerged as a viable alternative to traditional in-person rehabilitation programs, allowing patients with musculoskeletal conditions like tennis elbow to receive personalized exercise therapy, ergonomic guidance, and self-management strategies from a distance. Studies have shown that telerehabilitation programs are as effective as traditional in-person interventions regarding pain relief, functional improvement, and patient satisfaction.

However, with the expansion of telemedicine and remote rehabilitation services, patients can now access virtual consultations and telerehabilitation programs from the comfort of their own homes via a smartphone, tablet, or computer. Through secure video conferencing platforms and digital health applications, patients can interact with healthcare providers, receive personalized treatment recommendations, and participate in guided exercise therapy sessions tailored to their needs and goals.

Moreover, telerehabilitation platforms may include wearable sensors, motion-tracking devices, and interactive tools to track patient progress, provide real-time feedback, and ensure adherence to prescribed exercise regimens. Healthcare providers can use technology-enabled remote monitoring and communication to assess patient outcomes, adjust treatment plans as needed, and optimize rehabilitation outcomes, thereby improving the efficiency and effectiveness of tennis elbow management.

Regional Analysis

The global tennis elbow treatment market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global tennis elbow treatment market shareholder and is estimated to grow at a CAGR of 5.6% over the forecast period. The increasing number of sporting events and competitions in the United States and rising patient awareness are critical drivers of revenue growth in this region's tennis elbow treatment market. The rapidly growing elderly population and favorable reimbursement policies are expected to drive regional demand. Furthermore, the region's population is experiencing an increase in sport-related and tennis elbow injuries as the number of sporting events and competitions grows, particularly in the United States. This is expected to increase demand for various treatment options that reduce pain while speeding up healing. According to GJEL data published in June 2022, the five most dangerous sports that caused the most injuries in 2021 were basketball (2,823 injury cases), American football (1,719), soccer (1,289), baseball (347), and boxing (247 injury cases).

Additionally, according to the same source, sprains and strains accounted for 37% of all basketball injuries, compared to 29% for soccer and 26% for American football, making them the most common injuries for the three most dangerous sports in the US. Ligament discomfort was the primary injury in 23% of basketball and soccer cases. Thus, the prevalence of sports injuries, sprains, and strain issues raises the risk of elbow dislocation or fracture. This is expected to boost demand for medications and surgery, driving market growth.

Furthermore, according to a September 2021 news report, Korsh Jafarnia presented the findings of its study at the American Academy of Orthopaedic Surgeons Annual Meeting, demonstrating that hyaluronic acid injection is effective in relieving pain and improving function in patients with chronic tennis elbow. Furthermore, patients who received hyaluronic acid injections showed significant improvements in VAS pain scores, patient-rated tennis elbow evaluation, and QuickDASH scores. As a result, such studies are expected to increase the demand for medications used to treat elbow injuries, thereby driving market growth. Prominent players in the region contribute significantly to the North American tennis elbow treatment market's revenue growth. 

Asia-Pacific is anticipated to exhibit a CAGR of 5.9% over the forecast period owing to an increase in the prevalence of tennis elbow due to more athletic accidents and increased public awareness of the condition. For example, in April 2023, Pakistani fast bowler Ihsanullah suffered an elbow injury during a white-ball series against New Zealand. Furthermore, the growing adoption of advanced technologies and emerging healthcare infrastructure helps to drive revenue growth in this region's tennis elbow treatment market. 

The European tennis elbow treatment market is driven by factors such as the rising prevalence of musculoskeletal disorders, increased sports participation, and advancements in treatment modalities. According to the European Union (EU), musculoskeletal disorders (MSDs) are the most common workplace health issues, affecting approximately 45 million workers. With a diverse population and varying healthcare systems across European countries, the market displays dynamic trends influenced by regulatory policies, healthcare infrastructure, and patient preferences.

Segmental Analysis

The global tennis elbow treatment market is segmented based on treatment type and Application.

The market is further segmented by treatment type into Surgical Therapies and non-surgical Therapies.

The segment of non-surgical therapies is expected to grow at the fastest CAGR during the forecast period. Non-surgical therapies include a wide range of conservative treatment options that aim to alleviate pain, reduce inflammation, and promote healing without the use of invasive procedures. To manage pain and inflammation, these treatments may include rest, activity modification, and the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Physical therapy is frequently recommended to strengthen muscles, increase flexibility, and improve biomechanics. Corticosteroid injections to reduce inflammation, orthotic braces to offload the affected tendon, and shockwave therapy to stimulate tissue repair are all possible non-surgical treatments. Non-surgical therapies are a less invasive alternative to surgery and are commonly used as the first line of treatment for most cases of tennis elbow.

Tennis elbow surgery is usually considered when conservative treatments fail to provide adequate relief. One common surgical approach is lateral epicondyle release, which involves removing damaged tendon tissue and relieving tension on the extensor tendons. Another option is arthroscopic surgery, which uses a small camera and instruments inserted through tiny incisions to repair or remove damaged tissue. Surgical therapies seek to relieve pain, restore function, and promote healing by addressing underlying tendon damage and inflammation. While effective, surgical interventions are associated with risks such as infection, nerve injury, and prolonged recovery, so they are only recommended for severe or refractory tennis elbow.

The market can be bifurcated by Application into Children, Youth, and Elderly.

Tennis elbow among older people can be caused by age-related changes in tendon structure, decreased muscle strength, and degenerative processes. Tennis elbow symptoms in older adults aged 50 and up may be exacerbated by osteoarthritis and tendons that have worn down over time. Tennis elbow treatment in older people focuses on pain relief, function preservation, and improved quality of life. Non-surgical interventions, such as physical therapy, orthotic braces, and assistive devices, are frequently preferred, with surgical options reserved for severe or persistent cases. Tennis elbow in older people is managed comprehensively by addressing comorbidities, optimizing nutrition, and promoting lifestyle changes to support overall health and well-being.

Youth, including adolescents and teenagers, are also susceptible to tennis elbow, especially those participating in sports and physical activities. Youth, like children, can develop tennis elbow due to overuse, improper technique, or sports-related injuries. Tennis elbow treatment in youth focuses on conservative measures such as rest, anti-inflammatory medications, physical therapy, and training technique modifications to optimize recovery and prevent future injury. Youth athletes must be educated on injury prevention and proper biomechanics to ensure long-term musculoskeletal health.

Recent Developments

• February 2024- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company that manufactures and sells non-invasive medical devices for pain management, rehabilitation, and patient monitoring, launched two new therapy products: the Zynex Pro Hybrid LSO and the Zynex DynaComp Cold Compression.
• April 2024- Ottobock launched several groundbreaking initiatives to increase mobility, advocacy, and access to prosthetic and orthotic devices.